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Abstract: 
Mycobacterium tuberculosis (Mtb) is the bacteria for causing TB in human. H37Rv strain is responsible 
for this disease. Among the bacterial infectious diseases it is the leading cause of deaths in the world.  
According to statics it kills 30000 people per year in India. Multi-drug-resistant tuberculosis (MDR TB) 
shows resistance against these effective drugs- isoniazid and rifampicin. In this approach we have found 
certain target protein which can give rise to novel drug for this disease. All the metabolic pathways 
which are not present in the human but present in pathogen are taken as unique pathways. Here there are 
five such pathways which unique and are present only in bacteria. The genes responsible for these 
unique pathways were listed and were analyzed for their essentiality for the survival of the pathogen 
from the DEG (Database of Essential Genes). The essential genes were then blasted against the human 
genome through BLASTP. The structures and functions of non-homologous proteins were then 
analyzed. 
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1. INTRODUCTION: 
Tuberculosis is a highly contagious air borne disease.  It is believed that that originate from soil. It is 
postulated that Mtb has originated from mycobacterium bovis, which infects primates and ruminants. 
During 5000 B.C when man domesticated cattle this strain was introduced into man. This strain 
underwent a complex process of evolution and host adaptions, inside the human organs to become 
tubercle bacillus, causing TB [1]. 
It is one of the leading bacterial diseases. It kills about 1.1 million peoples over the world, an additional 
0.35 million deaths were due to HIV-associated tuberculosis. India shares a big portion of this figure [2]. 
The existing drugs, have several shortcomings, the most important is the emergence of drug resistance 
strain developed due to this drugs and as a result frontline drugs are inactive. Secondly, they make the 
patient incompliance. Another important problem with most of the existing antimycobacterials is their 
inability to act upon latent forms of the bacillus. In addition to these problems, the vicious interactions 
between the HIV (human immunodeficiency virus) and TB have led to further challenges for 
antitubercular drug discovery [3]. The mycobacterial cell wall envelope is thick, rigid, and waxy and 
consists of inner lipid bilayer plasma membrane. The cell wall is formed by peptidoglycan-
arabinogalactan polymers in periplasmic space with outer lipid enriched in mycolic acids covalently 
Linked To The Arabinogalactan Layer [4]. 
1.1. Mode of Infection and Symptoms: 
Mycobacterium tuberculosis can only infect a healthy person from an infected person. The mode of 
transfer of this bacteria are coughing, sneezing and talking of infected person can release the bacteria 
into the surrounding air and the people breathing this air get infected. It primarily infect the lungs but 
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also has severe effects on central nervous system, lymphatic system, circulatory system among other 
organs [5]. 
When this disease infect humans it shows a range of symptoms  such as severe cough, fever, chills, night 
sweets, loss of appetite, severe weight loss, blood in sputum,etc.  A person who does not show any 
symptoms of the active disease is referred as inactive TB. Someone with a healthy immune system has 
10% lifetime chances for reactivating this inactive bacterium into active symptoms of TB. But if the 
person is suffering from AIDS or other weakness diseases that suppress the immune system, then the 
chance of reactivating increases to 10% each year.  The other weakness diseases include: 
1. Diabetes. 
2. Head or neck cancer. 
3. Kidney disease. 
4. Long term steroid use. 
5. Malnutrition 
6. Medications that suppress the immune system, such as anticancer medications (e.g., cyclosporine, 
tacrolimus). 
1.2 Earlier Therapeutic Approach: 
In early 1930s and 1940s antibiotics like Penicillin and Sulfa drugs were used, but it soon became 
evident that this bacterium was resistant to these drugs. In the year 1943, Selman Waksman found 
Streptomycin as anti-tuberculosis agent. After few years until 1948, it was found that a new strain was 
developed which was resistant to Streptomycin. Then two new drugs para-aminosalicylic acid and 
thiacetazone were developed. When these two drugs in combination with Streptomycin were used the 
antibiotics resistance strain was reduced significantly. In 1951 isoniazid (isonicotinic acid hydrazide) 
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was proved be best clinical outcomes but for few years. Followed by isoniazid, there were few more 
new drugs emerged for mutant strain such as pyrazinamide (1952), cycloserine (1952), ethionamide 
(1956), rifampicin (1957) and ethambutol (1962). 
So here the first line of drugs are: isonazide amd rimpicin, pyrazinamide, ethambutol and streptomycin. 
According to DOTS (directly observed therapy, short-course), the sputum is tested and first line of drugs 
are being administered. The disadvantages of this method are : 
i. The treatment regime is 6-9 months. 
ii. Side-effects such as vomiting, dizziness and skin rashes to drug induced hepatitis. 
The irregular intake of medicine causes MDR-TB (Multiple Drug Resistant TB), and here the first line 
of drugs fail [6]. 
1.3 Objective: 
The objective of this project is to identify a gene of unique metabolism pathways which can act a target 
for mycobacterium tuberculosis. That gene should be non-homologous to host(here human). 
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2. LITERATURE REVIEW: 
NCBI: 
National Center for Biotechnology Information (NCBI), it is a part of the United States National Library 
of Medicine. It contains the tools such as BLAST (for sequence similarity), GenBank (provide the 
nucleotide sequence), PubMed [7]. 
BLASTP: Basic Local Alignment Search Tool. It is a tool used to compare a query sequence of 
nucleotides with a database of sequence to identify the similarity between the two sequences above a 
threshold [8].  BLASTP: Here the amino acid sequence is compared. As a result, it gives clear 
information about the similarity of genes and which is related to some protein. 
KEGG: 
Kyoto Encyclopedia of Genes and Genomes is a set of database of biological pathways, diseases, drugs, 
chemical substances []. Used for analysis of genomics, metagenomics and metabolomics. It is an 
accumulation of pathway maps incorporating numerous substances including genes, proteins, RNAs, 
substance mixes, glycans, and compound responses, and in addition disease genes and targets, which are 
put away as individual entrances in alternate databases of KEGG[9].  
DEG: 
Database of Essential Genes, is a database and provide tool to analysis the essentiality of the gene [10]. 
Essential genes are those genes of an organism that are thought to be critical for its survival of the 
organism. 
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UNIPORT: 
It gives information of the gene about the function, sequence and location in the cell. UniProt 
Knowledgebase is a protein database partially curated by experts, consisting of two sections: 
UniProtKB/Swiss-Prot (containing reviewed, manually annotated entries) and UniProtKB/ TrEMBL 
(containing unreviewed, automatically annotated entries) [11]. 
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3. MATERIALS METHODS: 
3.1 Selection of Unique Pathways: 
KEGG data base is used to select the unique pathways from human and mtb. It has been found that there 
are some unique pathways found in the bacteria [5]. 
Fig: 1 (Pathways of Mtb) 
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The unique pathways are listed here: 
1. Carbohydrate metabolism 
(a) c5-Branched dibasic acid metabolism. 
2. Energy metabolism 
(a) Carbon fixation pathway in prokaryotes. 
(b) Methane metabolism. 
3. Lipopolysaccharide biosynthesis. 
4. Peptidoglycan biosynthesis. 
Here we have selected four (excluding carbon fixation in prokaryotes) among the five pathways, 
because here we have concentrated towards the genes of plasma membrane/ cell wall for vaccination 
purpose.  
 
 
 
 
3.2 List of genes: 
Steps to be followed to get the list of all genes are: 
Open KEGG websitemetabolism pathwayselect the pathway listed abovein the dropdown box 
select the mycobacterium tuberculosis H37Rvclick on Go pathway entry. 
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A page will open, which will contain the list of genes and shown as: 
 
Fig: 2 snapshot of KEGG database contains list of genes. 
All the genes involved in these pathways are listed down: 
1. C5-Branched dibasic acid metabolism  
1. mtu:Rv0951 
 
sucC; Probable succinyl-CoA synthetase (beta chain) SucC (SCS-beta);         
K01903 succinyl-CoA synthetase   
2. mtu:Rv0952 
 
sucD; Probable succinyl-CoA synthetase (alpha chain) SucD (SCS-alpha);                 
K01902 succinyl-CoA synthetas  
3. mtu:Rv1820 
 
ilvG; Probable acetolactate synthase IlvG (acetohydroxy-acid  
synthase)(ALS); K01652 acetolactate syn  
4. mtu:Rv2987c leuD; Probable 3-isopropylmalate dehydratase (small subunit) LeuD  
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 (isopropylmalate isomerase) (alpha  
5. mtu:Rv2988c 
 
leuC; Probable 3-isopropylmalate dehydratase (large subunit) LeuC  
(isopropylmalate isomerase) 
6. mtu:Rv3002c 
 
ilvN; Probable acetolactate synthase (small subunit) IlvN (acetohydroxy-acid  
synthase) (AHAS) (ALS);  
7. mtu:Rv3003c 
 
ilvB1; Acetolactate synthase (large subunit) IlvB1 (acetohydroxy-acid  
synthase); K01652 acetolactate  
8. mtu:Rv3470c 
 
ilvB2; Probable acetolactate synthase (large subunit) IlvB2 (AHAS)  
(acetohydroxy-acid synthase large  
 
 
 
 
2. Methane metabolism: 
1. Rv0761c adhB; Possible zinc-containing alcohol dehydrogenase NAD dependent 
AdhB [KO:K00121] [EC:1.1.1.1 1.1.1.284] 
2. Rv3086 adhD; Probable zinc-type alcohol dehydrogenase AdhD (aldehyde 
reductase) [KO:K00121] [EC:1.1.1.11.1.1.284] 
3. Rv0374c Probable carbon monoxyde dehydrogenase (small chain); K03518 carbon-
monoxide dehydrogenase small subunit [EC:1.2.99.2] [KO:K03518] 
[EC:1.2.99.2] 
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4. Rv0375c Probable carbon monoxyde dehydrogenase (medium chain); K03519 
carbon-monoxide dehydrogenase medium subunit [EC:1.2.99.2] 
[KO:K03519] [EC:1.2.99.2] 
5. Rv0373c Probable carbon monoxyde dehydrogenase (large chain); K03520 carbon-
monoxide dehydrogenase large subunit [EC:1.2.99.2] [KO:K03520] 
[EC:1.2.99.2] 
6. Rv0070c glyA2; Serine hydroxymethyltransferase GlyA2 (serine methylase 2) 
(SHMT 2) [KO:K00600] [EC:2.1.2.1] 
7. Rv1093 glyA1; Serine hydroxymethyltransferase 1 GlyA1 [KO:K00600] 
[EC:2.1.2.1] 
8. Rv1023 eno; Probable enolase Eno [KO:K01689] [EC:4.2.1.11] 
9. Rv1240 mdh; Probable malate dehydrogenase Mdh [KO:K00024] [EC:1.1.1.37] 
10. Rv0363c fba; Probable fructose-bisphosphate aldolase Fba [KO:K01624] 
[EC:4.1.2.13] 
11. Rv1099c glpX; Fructose 1,6-bisphosphatase GlpX [KO:K02446] [EC:3.1.3.11] 
12. Rv3010c pfkA; Probable 6-phosphofructokinase PfkA (phosphohexokinase) 
(phosphofructokinase) [KO:K00850] [EC:2.7.1.11] 
13. Rv2029c pfkB; 6-phosphofructokinase PfkB (phosphohexokinase) 
(phosphofructokinase) [KO:K16370] [EC:2.7.1.11] 
14. Rv0409 ackA; Probable acetate kinase AckA (acetokinase) [KO:K00925] 
[EC:2.7.2.1] 
15. Rv0408 pta; Probable phosphate acetyltransferase Pta (phosphotransacetylase) 
[KO:K13788] [EC:2.3.1.8] 
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16. Rv3667 acs; Acetyl-coenzyme A synthetase Acs (acetate--CoA ligase) (acetyl-CoA 
synthetase) (acetyl-CoA synthase) (acyl-activating enzyme) (acetate 
thiokinase) (acetyl-activating enzyme) (acetate--coenzyme A ligase) 
(acetyl-coenzyme A synthase) [KO:K01895] [EC:6.2.1.1] 
17. Rv0489 gpm1; Probable phosphoglycerate mutase 1 Gpm1 
(phosphoglyceromutase) (PGAM) (BPG-dependent PGAM) [KO:K01834] 
[EC:5.4.2.11] 
18. Rv2419c gpgP; Glucosyl-3-phosphoglycerate phosphatase GpgP [KO:K15634] 
[EC:5.4.2.12] 
19. Rv3214 gpm2; Possible phosphoglycerate mutase Gpm2 (phosphoglyceromutase) 
(PGAM) (BPG-dependent PGAM) [KO:K15634] [EC:5.4.2.12] 
20. Rv3837c Probable phosphoglycerate mutase (phosphoglyceromutase) 
(phosphoglycerate phosphomutase); K15634 probable phosphoglycerate 
mutase [EC:5.4.2.12] [KO:K15634] [EC:5.4.2.12] 
21. Rv2228c Multifunctional protein Has RNASE H; K15634 probable 
phosphoglycerate mutase [EC:5.4.2.12] [KO:K15634] [EC:5.4.2.12] 
22. Rv0728c serA2; Possible D-3-phosphoglycerate dehydrogenase SerA2 
(phosphoglycerate dehydrogenase) (PGDH) [KO:K00058] [EC:1.1.1.95] 
23. Rv2996c serA1; Probable D-3-phosphoglycerate dehydrogenase SerA1 (PGDH) 
[KO:K00058] [EC:1.1.1.95] 
24. Rv0884c serC; Possible phosphoserine aminotransferase SerC (PSAT) 
[KO:K00831] [EC:2.6.1.52] 
25. Rv3042c serB2; Probable phosphoserine phosphatase SerB2 (PSP) (O-
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phosphoserine phosphohydrolase) (pspase) [KO:K01079] [EC:3.1.3.3] 
26. Rv2983  Conserved hypothetical alanine rich protein; K14941 2-phospho-L-lactate 
guanylyltransferase [EC:2.7.7.68] [KO:K14941] [EC:2.7.7.68] 
27. Rv3261   fbiA; Probable F420 biosynthesis protein FbiA [KO:K11212] 
[EC:2.7.8.28] 
28. Rv3262   fbiB; Probable F420 biosynthesis protein FbiB [KO:K12234] 
[EC:6.3.2.34 6.3.2.31] 
 
 
3.Lipopolysaccharide biosynthesis: 
1. Rv2611c   Probable acyltransferase; K02517 lipid A biosynthesis lauroyl 
acyltransferase [EC:2.3.1.-] [KO:K02517] [EC:2.3.1.-] 
2. Rv0113   gmhA; Probable sedoheptulose-7-phosphate isomerase GmhA 
(phosphoheptose isomerase) [KO:K03271] [EC:5.3.1.28] 
3. Rv0114   gmhB; Possible D-alpha,beta-D-heptose-1,7-biphosphate phosphatase 
GmhB (D-glycero-D-manno-heptose 7-phosphate kinase) [KO:K03273] 
[EC:3.1.3.83 3.1.3.82] 
4. Rv0115   hddA; Possible D-alpha-D-heptose-7-phosphate kinase HddA 
[KO:K07031] [EC:2.7.1.168] 
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4 .Peptidoglycan biosynthesis: 
1. Rv1315   murA; Probable UDP-N-acetylglucosamine 1-carboxyvinyltransferase MurA 
[KO:K00790] [EC:2.5.1.7] 
2. Rv0482   murB; Probable UDP-N-acetylenolpyruvoylglucosamine reductase MurB (UDP-
N-acetylmuramate dehydrogenase) [KO:K00075] [EC:1.3.1.98] 
3. Rv2152c   murC; Probable UDP-N-acetylmuramate-alanine ligase MurC [KO:K01924] 
[EC:6.3.2.8] 
4. Rv2155c   murD; Probable UDP-N-acetylmuramoylalanine-D-glutamate ligase MurD 
[KO:K01925] [EC:6.3.2.9] 
5. Rv2158c   murE; Probable UDP-N-acetylmuramoylalanyl-D-glutamate-2,6-
diaminopimelate ligase MurE [KO:K01928] [EC:6.3.2.13] 
6. Rv2981c   ddlA; Probable D-alanine--D-alanine ligase DdlA (D-alanylalanine synthetase) 
(D-ala-D-ala ligase) [KO:K01921] [EC:6.3.2.4] 
7. Rv2157c   murF; Probable UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-
diaminopimelate-D-alanyl-D-alanyl ligase MurF [KO:K01929] [EC:6.3.2.10] 
8. Rv2136c   Possible conserved transmembrane protein; K06153 undecaprenyl-
diphosphatase [EC:3.6.1.27] [KO:K06153] [EC:3.6.1.27] 
9. Rv2156c   murX; Probable phospho-N-acetylmuramoyl-pentappeptidetransferase MurX 
[KO:K01000] [EC:2.7.8.13] 
10. Rv2153c   murG; Probable UPD-N-acetylglucosamine-N-acetylmuramyl-(pentapeptide) 
pyrophosphoryl-undecaprenol-N-acetylglucosamine transferase MurG 
[KO:K02563] [EC:2.4.1.227] 
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11. Rv3910   Probable conserved transmembrane protein; K03980 virulence factor 
[KO:K03980] 
12. Rv0016c   pbpA; Probable penicillin-binding protein PbpA [KO:K05364] [EC:2.4.1.129] 
13. Rv2163c   pbpB; Probable penicillin-binding membrane protein PbpB [KO:K03587] 
14. Rv2911   dacB2; Probable penicillin-binding protein DacB2 (D-alanyl-D-alanine 
carboxypeptidase) (DD-peptidase) (DD-carboxypeptidase) (PBP) (DD-
transpeptidase) (serine-type D-ala-D-ala carboxypeptidase) (D-amino acid 
hydrolase) [KO:K07258] [EC:3.4.16.4] 
15. Rv3330   dacB1; Probable penicillin-binding protein DacB1 (D-alanyl-D-alanine 
carboxypeptidase) (DD-peptidase) (DD-carboxypeptidase) (PBP) (DD-
transpeptidase) (serine-type D-ala-D-ala carboxypeptidase) (D-amino acid 
hydrolase) [KO:K07258] [EC:3.4.16.4] 
16. Rv3627c   hypothetical protein; K07259 D-alanyl-D-alanine carboxypeptidase / D-alanyl-
D-alanine-endopeptidase (penicillin-binding protein 4) [EC:3.4.16.4 3.4.21.-] 
[KO:K07259] [EC:3.4.21.- 3.4.16.4] 
 
 
 
3.3 Selection of essential genes: 
The essential genes are common to cells and are considered as foundation of life. The amino acid 
sequence are compared by using BLASTP of DEG. Importance of the above are analyzed through DEG 
(Database of Essential Genes), cut off score was set greater than 100, due to the specificity of the 
enzyme for the existence of the bacterial. 
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3.4 USE OF BLAST: 
Here BLASTP is being used discard the homologous genes. Homologous genes are genes that are 
present in the human being and plays important role. If we target the homologous genes than this will 
produce adverse effect in the biological process of the human being. So the identity below 15 % can be 
taken as target and expected value 0.005.  As we are targeting the multi resistant strain it would be better 
to target the most conserved domain of the bacteria. 
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4. RESULT AND DISCUSSION: 
4.1 List of Pathways with Figure: 
The unique pathway of KEGG website are as follows:  
1. c5-Branched dibasic acid metabolism. 
Fig:3 
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Methane  metabolism:
Fig:4 
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2. Lipopolysaccharide biosynthesis: 
 
Fig: 5 
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3. Peptidoglycan biosynthesis: 
 
Fig:6 
 
target 
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4.2 SELECTION OF ESSENTISL GENES: 
The essential genes are short out though the DEG database. The parameters that is being used to short 
out the genes is shown below, score greater than 100(i.e. 500), expected value is 1×℮0.5. This is taken 
due to specificity of the gene toward the metabolism process. 
 
 
Fig: 7 Parameters for the DEG 
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List of Essential Genes are: 
After submitting all the amino acid sequence of the genes of selected four pathways are retrieved from 
the DEG database or through mail. All the essential genes are shown below. 
 
Gene Entry Gene Name 
1. Rv1820 ilvG 
2. Rv0951 sucC 
3. Rv0761c adhB 
4. Rv0373c  
5. Rv0070c  glyA2  
6. Rv1023 Eno 
7. Rv1240 Mdh 
8. Rv0363c Fba 
9. Rv2029c pfkB 
10. Rv0409 ackA 
11. Rv0408 Pta 
12. Rv3667 Acs 
13. Rv0489 gpm1 
23 
 
14. Rv0728c serA2 
15. Rv2611c  
16. Rv0113 gmhA 
17. Rv0114 gmhB 
18. Rv0482 murB 
19. Rv2152c murC 
20. Rv2155c murD 
21. Rv2158c murE 
22. Rv2981c dd1A 
23. rv2157c murF 
24. Rv2136c  
25. Rv2156c murX 
26. Rv2153c  
27. Rv3910  
28. Rv0016c PbpA 
29. Rv2163c PbpA 
30. Rv1315 murA 
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4.3 BLAST: 
Result of the BLASTP of human genome against the shortlisted 30 genes. The threshold was set to 
0.005 and identity should be less than 35%. 
 
Fig: 8 Parameters for BLASTP 
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4.3.1 Result of the BLASTP: 
After pasting the amino acid sequence in the box provided, setting the parameters as shown above, then 
click on BLAST. A page will open after few second as such: 
 
Fig: 9 Analysis of the BLAST result in NCBI. 
 
This page will show the identity and detail information under description column. Detail information 
and the most valuable file format of the gene can be achieved by marking the gene in the provided box 
then clicking on the download or GenPept, graphical view for Graphics. We can reduce the number of 
column by clicking on the setting icon on top of right corner. 
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All the BLAST result is listed below with their EC number and biological process: 
 
 Accession No 
and Gene 
Name 
Location in 
cell and 
cellular 
components 
Can be 
used 
as 
target 
or not 
Biological processes Enzyme 
Commission 
Number  
1. Rv1820: ilvG Not known Yes Amino acid biosynthesis 2.2.1.6 
2. Rv0951: sucC Cytosol No Tricarboxylic acid cycle 6.2.1.5 
3. Rv0761c: adhb Cytoplasm, 
plasma 
membrane 
No Oxidoreductase 1.1.1.1 1.1.1.284 
4. Rv0373c Plasma 
membrane 
Yes Carbon monoxide dehydrogenase 1.2.99.2 
5. Rv0070c: 
glyA2 
Cytoplasm No Serine hydroxymethyltransferase 2.1.2.1 
6. Rv1023: eno Cytoplasm 
secreted 
No Tricarboxylic acid cycle 4.2.1.11 
7 Rv1240: mdh Cytosol, 
plasma 
membrane 
No Glycolysis 1.1.1.37 
8. Rv0363c: fba Plasma 
membrane 
Yes Glycolysis, protein 
homotetramerization 
4.1.2.13 
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9. Rv2029c: pfkB Not known Yes Carbohydrate metabolic process 2.7.1.11 
10. Rv0409: ackA Cytoplasm Yes Organic acid metabolic process 2.7.2.1 
11. Rv0408:pta Cytoplasm No Not known 2.3.1.8 
12. Rv3667:acs Plasma 
membrane 
No Not known 6.2.1.1 
13. Rv0489:gpm1 Plasma 
membrane 
No phosphoglycerate mutase 5.4.2.11 
14. Rv0728c:serA2 Not known Close 
to 
35%, 
No 
D-3-phosphoglycerate dehydrogenase 1.1.1.95 
15. Rv2611c:htrB Plasma 
membrane 
Yes Acyltransferase 2.3.1.- 
16. Rv0113:gmhA Cytoplasm Yes Carbohydrate metabolism 5.3.1.28 
17. Rv0114:gmhB Cytoplasm Yes Carbohydrate metabolism, histadine 
biosynthesis 
3.1.3.83 3.1.3.82 
18. Rv1315:murA Cytoplasm Yes Cell cycle, cell division 
Peptidoglycan biosynthesis, regulation 
of cell shape 
2.5.1.7 
19.  
Rv0482:murB 
Cytoplasm Yes -do- 1.3.1.98 
20. Rv2152c:murC Cytoplasm Yes            -do- 6.3.2.8 
21. Rv2155c:murD Cystol Yes -do- 6.3.2.9 
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22. Rv2158c:murE Plasma 
membrane 
Yes -do- 6.3.2.13 
23. Rv2981c:ddlA Plasma 
membrane 
Yes -do- 6.3.2.4 
24. Rv2157c:murF Cytoplasm Yes -do- 6.3.2.10 
25. Rv2136c Plasma 
membrane 
Yes -do-, antibiotic resistance 3.6.1.27 
26. Rv2156c:murX Plasma 
membrane 
Yes Cell cycle, cell division 
Peptidoglycan biosynthesis, regulation 
of cell shape 
2.7.8.13 
27. Rv2153c:murG Plasma 
membrane 
Yes -do- 2.4.1.227 
28. Rv3910 Plasma 
membrane 
Yes Conserved transmembrane protein  
29. Rv0016c:pbpA  plasma 
membrane 
Yes penicillin-binding protein 2.4.1.129 
30. Rv2163c:pbpB Extracellular  Yes penicillin-binding membrane protein  
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4.4 DISCUSSION: 
The NCBI Gene ID of  Rv 2981c is 888415, D-alanine--D-alanine ligase DdlA (D-alanylalanine 
synthetase) (D-ala-D-ala ligase). The catalytic activity of this protein is: ATP + 2 D-alanine = ADP + 
phosphate + D-alanyl-D-alanine. In this gene the magnesium binding site is present in the 318,330 and 
332 of the amino acid sequence. This metal binding site is also important for this gene, if these site can 
be blocked then the biological function of the bacteria will stop and a important target can be achieved 
for treatment. The amino acid sequence of this gene is : 
        10         20         30         40         50         60  
MSANDRRDRR VRVAVVFGGR SNEHAISCVS AGSILRNLDS RRFDVIAVGI TPAGSWVLTD  
 
        70         80         90        100        110        120  
ANPDALTITN RELPQVKSGS GTELALPADP RRGGQLVSLP PGAGEVLESV DVVFPVLHGP  
 
       130        140        150        160        170        180  
YGEDGTIQGL LELAGVPYVG AGVLASAVGM DKEFTKKLLA ADGLPVGAYA VLRPPRSTLH  
 
       190        200        210        220        230        240  
RQECERLGLP VFVKPARGGS SIGVSRVSSW DQLPAAVARA RRHDPKVIVE AAISGRELEC  
 
       250        260        270        280        290        300  
GVLEMPDGTL EASTLGEIRV AGVRGREDSF YDFATKYLDD AAELDVPAKV DDQVAEAIRQ  
 
       310        320        330        340        350        360  
LAIRAFAAID CRGLARVDFF LTDDGPVINE INTMPGFTTI SMYPRMWAAS GVDYPTLLAT  
 
       370  
MIETTLARGV GL 
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This can be taken as target protein, because of the following points: 
1. The 3D structure of the protein is known. 
2. It has given the best BLASTP result. 
3. This gene is responsible for the cell wall organization, regulation of cell shape. So, if gene is targeted 
the wall will disrupt and cell lysis will occur. 
4. If this protein is checked, the metabolism followed after this gene will not occur and hence the 
metabolism product will not present in human. 
5. As this gene is responsible for the cell wall organization, so the bacteria will not be able to go to 
dormant stage. 
4.5 Structure of the gene Rv2981c: 
 
Fig: 10 
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5. CONCLUSION: 
All the genes of the four important metabolism pathways which are not present in the human are taken 
as important pathways. The genes responsible for these pathways are listed and analyzed for their 
essentiality in the metabolism process of the bacteria through the DEG tool. All the shorted genes from 
the DEG are being shorted for the non-homologous for the human being through the NCBI BLAST. 
Here BLASTP is used, as BLASTP takes the amino acid sequence which is responsible for the protein 
present in the bacteria.  And the introns will not present in our sequence. After performing all the above 
steps we have been able to find a target named as Rv2981c, which is present in the cytoplasm of the 
bacterial cell. If this gene function can be stopped then the bacteria can be killed and Multiple Drugs 
Resistant TB can be cured. As this gene is responsible for the cell shape, cell wall biogenesis/ 
degradation and peptidoglycan synthesis. This will disrupt the cell wall and will lead to the death of the 
bacteria. 
The future scope of this project is to find a certain molecule which can be able to target this gene and the 
Multiple Drugs Resistant TB (MDR) can be cured.  
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